

海正

始于一九五六



# Corporate Brochure

(2025 Edition)

**COMPANY  
OVERVIEW**

**BUSINESS  
STRUCTURE**

**INTERNATIONAL  
BUSINESS**

**SYNTHETIC  
BIOLOGY**

**CORPORATE  
HONORS**

**CORPORATE SOCIAL  
RESPONSIBILITIES**

Company Profile 01  
Key Subsidiaries 03  
Corporate History 05

Overall Layout 07  
Center for Research &  
Development 08  
Center for Manufacturing  
Operations 09  
Center for Marketing  
& Sales 11

International Business 16

Business Introduction 17

Corporate Honors 18

Social Responsibilities 19

# CONTENTS



## COMPANY PROFILE

Zhejiang Hisun Pharmaceutical Co., Ltd. (SSE: 600267), founded in 1956, is a state-owned comprehensive pharmaceutical and healthcare group. The company focuses on research & development, manufacturing, and marketing & sales of innovative drugs, biologics, generic medicine, and high-quality APIs, and at the same time, it also strategically expands into emerging sectors including animal health, holistic wellness, and medical aesthetics. Leveraging its industrial technology transformation and manufacturing capabilities, Hisun has pioneered strategic investments in synthetic biology, establishing itself as a frontrunner in this field. The company remains steadfast in its commitment to "Hisun-quality" excellence, actively addresses national strategic healthcare priorities, and continues to build a globally influential Chinese pharmaceutical and health brand.

## OVERVIEW OF KEY SUBSIDIARIES OF HISUN PHARMACEUTICAL

### Controlled subsidiaries

Hanhui Pharmaceuticals Co., Ltd

Hisun Pharmaceutical (Hangzhou) Co., Ltd.

Hisun Pharmaceutical (Nantong) Co., Ltd.

Zhejiang Hisun Animal Health Products Co., Ltd.

Zhejiang Pharmaceutical Industry Co., Ltd.

Hisun Weilan Biotechnology Development (Hainan) Co., Ltd.

Hisun USA Inc.

Zhejiang Yunsyn Biotechnology Co.,Ltd

### Joint Ventures


Zhejiang BioRay Biopharmaceutical Co., Ltd.

Xellia (Taizhou) Pharmaceuticals Co., Ltd.

Zhejiang Zansheng Pharmaceutical Co., Ltd.

Zhejiang Hisun Sulikang Biotechnology Co., Ltd.

# COMPANY HISTORY



## BUSINESS LAYOUT

The company has a full value chain of R&D, manufacturing and sales, covering a wide range of pharm-business areas with well-proven operation systems

### Center for R&D

Institute of Innovative Drugs

Institute of Preparation

Institute of APIs

### Center for Manufacturing Operations

Taizhou, Fuyang, and Nantong Sites, and Hanhui Plant/Public Service  
Production Planning/Technical Department

Supply Chain Management/Engineering and Equipment/EHS Management  
Strategic Industrial Projects

Quality Management Headquarters

### Center for Marketing & Sales

Hospital sales headquarters

Channel and innovative business sales headquarters



Commercial sales headquarters

Industrial and international sales headquarters

Animal drug sales headquarters

## CENTER FOR RESEARCH & DEVELOPMENT

Dedicated to R&D of innovative drugs, generic drugs and APIs



# CENTER FOR MANUFACTURING OPERATIONS

Localized management  
Rich product categories and sufficient production capacity



## API manufacturing

### API workshops

- ~10,000 m<sup>3</sup> of fermentation capacity
- ~2,000 m<sup>3</sup> of synthetic reaction capacity

Products:  
Anti-tumor, anti-infective, cardiovascular, antidiabetic, and veterinary drugs, and more



Taizhou production site Covers an area of 1035 mu (about 69 hectares)

### API workshops

- ~10,000 m<sup>3</sup> of fermentation capacity

Products:  
Immuno-suppressant, anti-infective, metabolic, and veterinary drugs, and more



Fuyang production site Covers an area of 1500 mu (about 100 hectares)

### API workshops

- ~10,000 m<sup>3</sup> of synthetic reaction capacity

Products:  
Cardiovascular, anti-infective, and veterinary drugs, and more



Nantong production site Covers an area of 405 mu (about 27 hectares)

## Preparation manufacturing

### Production Lines

- Oral preparation lines (Immuno-suppressant, anti-tumor, and general)
- Injection lines (General lyophilized products)

### Production Lines

- Oral preparation lines (General oral products)
- Injection lines (General lyophilized products, sterilized injections, and lyophilized anti-tumor products)

### Production Lines(HANHUI PHARMA)

- Oral preparation lines (General products and hormones)
- Injection lines (Lyophilized anti-tumor products, penem powder for injection, lyophilized penicillin, lyophilized hormones, and insulin preparations)

# The Quality System Adopted By Manufacturing Is Up To Global Standards



Since the 1990s, Hisun had gradually established a sound and comprehensive quality management system, validated through decades of collaboration with multinational enterprises such as Pfizer, Eli Lilly, Merck, and Sanofi.

## Comprehensive System



Supported by a highly specialized SMEs team and a dedicated regulatory analysis department, Hisun ensures the proactive compliance of the quality system with evolving regulatory requirements.

## Professional Quality Team



Over the years, Hisun has implemented a suite of electronic management systems, including LIMS, CAPA tracker, DMS, QRS (Quality Review System), and COA system; we are actively deploying MES system for drug product manufacturing.

## Electronic Management System



Hisun has successfully completed numerous official audits by international regulatory authorities, including those in the EU, US, Japan, and other regions, accumulating extensive compliance experience. The capabilities extend to remote audit management, demonstrated by passing back-to-back virtual inspections by the TGA and the EMA.

## Extensive Audit Experience

## CENTER FOR MARKETING & SALES



### Human drug

Cardiovascular, metabolic, anti-infective, oncology, and more

Deepen core pharmaceutical focus to steadfastly build an innovation-driven ecosystem for next-gen healthcare

Disease area	Usage	Key Products (Trade Name)	Generic Name
Cerebrovascular & Metabolic Diseases	Antihyperlipidaemia	Saisimei	Hybutimibe Tablets
	Lipid-lowering + Antihypertensive	Duodayi	Amlodipine Besylate and Atorvastatin Calcium Tablets
	Weight loss	Yixianying	Orlistat Tablets
Infectious Diseases	Bacterial infection	Tezhixing	Piperacillin Sodium and Tazobactam Sodium for Injection
		Meiman	Minocycline Hydrochloride Capsules
	Fungal infection	Haidaxin Yingtē	Posaconazole Enteric-coated Tablets/Posaconazole Injection Miconazole Sodium for Injection
	Tuberculosis	Sailaixing	Cycloserine Capsules
	Antiviral	Haifukang	Favipiravir Tablets
Hematological Neoplasms	Antineoplastic	—	Mitomycin for Injection
Autoimmune Diseases & Inflammatory Diseases	Immunosuppression Inhibiting Inflammatory Response	Jiaqianglong Meizhuole	Methylprednisolone Sodium Succinate for Injection Methylprednisolone Tablets
Collaborative Drug with International Pharmaceutical Companies in China	Bacterial infection	Niuzailē (Novartis)	Omadacycline Tosilate for Injection/Tablets
	Chronic obstructive pulmonary disease	Ultibro® (Novartis)	Indacaterol Maleate and Glycopyrronium Bromide Powder for Inhalation, Hard Capsules
	Anti-rejection in Solid Organ Transplant	Leipaming (Pfizer)	Sirolimus Tablets
	Antihyperglycemic	Ruiyining (Pfizer)	Glipizide Extended Release Tablets
Muscle & Orthopedic Disorders	Primary and secondary osteoarthritis	Yisuojia	Glucosamine Sulfate Capsules



## CENTER FOR MARKETING & SALES



### Animal Drug

Companion animal and economic animal

Build a closed loop of health care, prevention, and treatment to become a comprehensive solution provider for animal health

Type of Animal	Type of Product	Products
Companion Animal	Chemical Drugs	Milbemycin Oxime and Praziquantel Tablets/Milbemycin Oxime Tablets/Milbemycin Oxime and Praziquantel Chewable Tablets/Se-lamectin Spot-on Solution/Imidacloprid and Moxidectin Spot-on Solutions/Amoxicillin and Clavulanate Potassium for Suspension/Amoxicillin and Clavulanate Potassium Tablets/Cefpodoxime Proxetil Chewable Tablets
	Vaccines	Feline Rhinotracheitis - Calici - Panleukopenia Vaccine, Inactivated (Strain WH - 2017+Strain LZ - 2016+Strain CS - 2016)
Economic Animal	Chemical Drugs	Moxidectin Pour-on Solution/Fenbendazole Oral suspension/Doramectin Injection/Eprinomectin Pour-on Solution/Compound Amoxicillin Powder/Flunixin Meglumine Granules/Tilmicosin Premix/Tulathromycin Injection/Ceftiofur Hydrochloride Injection/Hai Ti Shu/Cefquinome Sulfate Intramammary Infusion (Dry Cow)/Bismuth Subnitrate Intramammary Infusion (Dry Cow)/Compound Amoxicillin Intramammary Infusion (Lactating Cow)
	Vaccines	Porcine Circovirus Type 2 and Swine Mycoplasma Hypopneumoniae Vaccine, Inactivated (Recombinant Baculovirus Strain DBN01 + Strain DJ-166)/Porcine Circovirus Type 2 Subunit Vaccine (E.coli Origin)/Classical Swine Fever Vaccine, Live (Cell Line Origin)

15

15 National Class - II New Veterinary Drugs (Preparations)

800 million +

Over 800 Million Total Investment

2

2 Chemical Drug & Vaccine Production Site

TOP5

Strategic Partner of Animal Health Enterprises Worldwide

40%

40% Global Market Share of Non-Patent Anthelmintic Drugs

## CENTER FOR MARKETING & SALES

Channel and innovative business sales headquarters

### Operation + channel expansion to promote sales coverage

Hisun optimizes the flow of logistics, capital, and channel data across our pharmaceutical sales process through internal operations refinement, tender admission maintenance and expansion of external distribution networks. This empowers Hisun to adapt to industry shifts and business evolutions. Beyond tiered hospital markets, Hisun drove OTC retail penetration, and achieved the commercial coverage of broad and grassroots emerging-channel markets to meet sales objectives.

#### Commercial Shipments

Deliver on commercial sales targets and ensure timely, full recovery of payments

#### Tendering and Admission

Oversee centralized procurement, online listing, government procurement, and related affairs; provide support for and manage the data of tender projects

#### Commercial Support

Deliver efficient back-end operations to provide fundamental and data-driven support to all business operations

#### E-commerce (by Hisun Weilan)

Professional online sales platform for vertically integrated wellness beauty products and formulations

#### Retail Sales

Expand and manage OTC retail channels, engage with national-level general distributors and all levels of sales terminals for retail pharmaceuticals

210

About 210 primary-level distributors across China

90

90+ product specifications sold

7

7+ delivery platforms & manufacturing partners

600

600+ strategic chain-store customers nationwide

89%

89% store penetration with 7 major NKA chains

31%

31% coverage with over 120,000 domestic chain stores

## CENTER FOR MARKETING & SALES



APIs

100+

APIs for human use

- Antineoplastics
- Anti-infection
- Cardiovascular
- Immunosuppressants

APIs for animal use

70+

Overseas revenue contributes over 80% of total sales  
Multiple API products occupy dominant market positions in major developed economies and EU markets

400+

Collaborate with leading global pharmaceutical companies

Leverage flexible engagement models to align with client needs

Committed to long-term stable supply of high-quality products



## CENTER FOR MARKETING & SALES

## INTERNATIONAL BUSINESS

Deliver high-quality products through a rigorous medical R&D, production, and management system  
Build a vertically integrated wellness beauty platform in China

### Emerging Businesses

Holistic health solutions, medical cosmetology and other non-drug offerings

Accelerate the advance of international business arrangements  
Reclaim a leadership position in the global mid-to-high-end pharmaceutical market

### International Business

APIs, drug products, veterinary drugs, medical aesthetics and e-commerce

# SYNTHETIC BIOLOGY

## Hisun Pharmaceutical Building a Leading Innovation Hub for Synthetic Biotechnology

Hisun Pharmaceutical has established a series of advanced technology platforms, including fermentation engineering, enzyme engineering, genetic engineering, as well as pilot-scale and production scale-up technology platforms.

Leveraging its existing industrial capabilities, the company actively strengthens collaborations with technology-driven enterprises to fully optimize production capacity and enhance resource utilization efficiency. Meanwhile, it is progressively exploring synthetic biology technologies to continuously boost innovation in emerging industrial fields.


Hisun Pharmaceutical is swiftly expanding its portfolio with market-aligned, rationally scaled pharmaceutical products. By establishing subsidiaries dedicated to cutting-edge synthetic biology R&D, the company focuses on developing high-value-potential products. Additionally, it continues to refine its R&D team, ensuring seamless transition from technology acquisition to commercial production.

The company prioritizes the advancement of core platform technologies, engaging in in-depth collaborations with research institutions and industry partners to drive the development of frontier technologies. Through careful selection of high-value-added products, it continuously optimizes and upgrades its product pipeline while steadily expanding into downstream industrial chains.

# HONOR



- One of China's first batch of national innovative enterprises
- Top 100 Chinese pharmaceutical innovation enterprises
- National technological innovation demonstration enterprise
- National engineering (technology research) center
- National Enterprise Technology Center
- National postdoctoral center
- Zhejiang provincial key laboratory
- Awarded 14 national and provincial science and technology awards, including 4 national awards
- The independently developed class 1 new drug, Hybutimibe, won the first prize of the Chinese Pharmaceutical Association Science and Technology Award
- Awarded 7 Patent Excellence Awards of National Intellectual Property Demonstration Enterprise
- Embedded ESG principles into core business operations
- Actively undertake critical national strategic demand tasks with products such as Tamiflu, anti-Ebola drugs and Favipiravir
- Awarded the title of "Advanced Collective in Combating COVID-19 (Industrial and IT Sector)", and received commendation from the National Development and Reform Commission for H1N1 response
- National excellent smart factory
- National manufacturing single champion enterprise
- Subsidiary Hanhui Pharmaceutical won the Zhejiang Provincial Government Quality Award
- Hisun Pharmaceutical earned a Bronze Medal from EcoVadis (internationally recognized sustainability rating platform) and ranked among the top 35% of global enterprises for our outstanding environmental, social, and governance (ESG) performance



## SOCIAL RESPONSIBILITY



### Undertaking national assignments for strategic needs

- Prioritize the production and capacity expansion of shortage varieties, resist the pressure of rising costs and profit losses of single drugs, and supply social shortage drugs. Actively help people solve the problem of drug shortage.
- Products such as oseltamivir, anti-Ebola drugs, tigecycline (for treating drug-resistant "super bacteria" ), and cycloserine (for treating tuberculosis) have helped patients in many countries, demonstrating Hisun's responsibility and commitment as a domestically-rooted pharmaceutical enterprise.

### Actively support the country's epidemic prevention and control efforts

- During the COVID-19 epidemic, favipiravir tablets produced by the company were quickly approved for marketing, contributing to global pandemic mitigation;
- In the fight against the COVID-19 epidemic in 2020, 5,000 Methylprednisolone Sodium Succinate for Injection, 500 Imipenem and Cilastatin Sodium for Injection and 100 Tigecycline for Injection were donated to designated medical institutions in Wuhan
- The company has received many letters of thanks from the Joint Prevention and Control Group of the State Council, the Ministry of Science and Technology, and the Zhejiang Provincial Medical Supplies Protection Group, and has been praised as a well-deserved "military factory" to fight the epidemic.
- The Ministry of Industry and Information Technology awarded Hisun Pharmaceutical the title of "Advanced Collective in Combating COVID-19 (Industrial and IT Sector)"

### Actively participate in social welfare initiatives

- Hisun established 6 book corners for Tengchong Primary School as part of the "Sunflower Charity Project"
- Since 2013, Hisun has participated in the "Red Phoenix Project" in Shaanxi Province, offering scholarships to a total of 40 financially-disadvantaged female college students
- In 2019, Hisun established the "Hanhui Cedar Class", offering scholarships to 50 high school students and helping them complete their three-year high school education
- In December 2021, Hanhui Pharmaceutical partnered with Bijie Medical College to establish an "industry-education integration center" to bridge the industry-academia gap and enhance talent quality

